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Autophagy is a cell-autonomous, catabolic process that plays context-dependent roles in tumor
growth and progression. Wei et al. report that EGFR signaling promotes tumor growth through
phosphorylation and functional inactivation of Beclin 1 and the consequent suppression of
autophagy.Macroautophagy (hereafter termed auto-
phagy) is a degradative process that
involves the encircling of cytoplasmic
elements by a specialized endomem-
brane structure (the autophagosome),
which delivers the cargo to lysosomes
for degradation and recycling into cellular
metabolic pathways. Autophagy supports
cell survival during metabolic stress
and maintains normal homeostasis by
ridding the cell of protein aggregates
and dysfunctional organelles (Choi et al.,
2013). Although autophagy is clearly rele-
vant to cancer biology, studies to date
paint a rather muddled picture, which
indicates that autophagy either sup-
presses or promotes tumor growth,
depending on cancer subtype and the
stage of tumor development (White,
2012). The report by Wei et al. (2013) in
this issue of Cell defines a novel pathwaythrough which the epidermal growth
factor receptor (EGFR) suppresses auto-
phagic activity to promote the growth of
non-small-cell lung cancers (NSCLCs).
The core components of the autopha-
gic machinery are conserved in eukary-
otic cells. Two critical proteins involved
in the initiation of autophagy are the class
III phosphoinositide 3-kinase, VPS34, and
the protein serine-threonine kinase, ULK1
(see Figure 1). VPS34 activation leads to
the localized accumulation of phosphati-
dylinositol 3-phosphate, which stimulates
endomembrane events required for auto-
phagosome formation (Lorin et al., 2013).
VPS34 activity is regulated, in part,
through binding to Beclin 1, a scaffolding
protein that has been identified as a
haploinsufficient tumor suppressor (Choi
et al., 2013; Lorin et al., 2013). Beclin 1
governs autophagy through interactionswith proteins that either stimulate
(ATG14L, UVRAG, and AMBRA1) or sup-
press (Bcl-2, Bcl-xL, and Rubicon)
VPS34 activity. The scaffolding functions
of Beclin 1 are directly modulated by a
growing number of protein kinases,
including mTOR, AMPK, ULK1, and AKT
(Lorin et al., 2013; Russell et al., 2013).
The EGFR tyrosine kinase is overex-
pressed or mutationally activated in a
broad range of human cancers, including
NSCLC. Previous reports indicated that
EGFR activation suppresses autophagy
and that TKI exposure triggers increased
autophagic flux in NSCLC cells (Fung
et al., 2012; Han et al., 2011). However,
the interplay between EGFR signaling
and the autophagy machinery, as well as
the role of autophagy in EGFR-driven
tumor growth, remained unclear. Wei
et al. (2013) demonstrate that Beclin 1
Figure 1. Multiple Protein Kinases Target Beclin 1 and Regulate the
Beclin 1 Interactome
EGFR signaling activates the class I PI3K-AKT-mTORC1 pathway. AKT and
mTORC1 phosphorylate Beclin 1 on serine residues, leading downregulation
of VPS34 activity and autophagy. In contrast, the ULK1 and AMPK kinases
stimulate autophagy by phosphorylating Beclin 1 and promoting the formation
of the active Beclin 1-VPS34 complex. mTORC1 also suppresses autophagy
initiation by phosphorylating and inhibiting ULK1. Wei et al. (2013) demon-
strate (red arrows) that the EGFR tyrosine kinase phosphorylates Beclin 1 and
drives the formation of Beclin 1 homodimers that do not support VPS34
activity, thereby inhibiting autophagy. These EGFR-dependent events are
blocked by TKIs.binds to and is a substrate for
the activated EGFR tyrosine
kinase. Tyrosine phosphory-
lation of Beclin 1 provokes
disassembly of the Beclin 1-
VPS34complex and the asso-
ciation of Beclin 1 with two
suppressors of autophagy,
Rubicon and Bcl-2. The net
result of this rearrangement
of the Beclin 1 ‘‘interactome’’
(as termed by the authors) is
that VPS34 activity and, in
turn, autophagy, are sup-
pressed in response to EGFR
activation. Exposure of
NSCLCcells to EGFR tyrosine
kinase inhibitors (TKIs) re-
stores the interaction of Beclin
1 with VPS34 and triggers an
increase in autophagy.
Notably, this mechanism of
autophagy regulation is inde-
pendent of EGFR-dependent
mTOR complex 1 (mTORC1)
activation, a well-established
mechanism of autophagy
downregulation. In the
NSCLC setting, modulation
of the Beclin 1 interactome
appeared to be a dominantmechanism for autophagy suppression
by the activated EGFR. This outcome
may reflect a relatively inefficient coupling
of EGFR signaling to PI3K signaling,
possibly due to suboptimal expression of
the HER3 subunit in the NSCLC cells (Si-
thanandam and Anderson, 2008). Inter-
estingly,Wei et al. (2013) reported that Be-
clin 1 tyrosine phosphorylation is not
induced by the PDGF receptor, which
strongly activates the PI3K-mTOR
pathway. Thus, the relative contributions
of the Beclin 1-VPS34 versus PI3K-
mTOR mechanisms to the regulation of
autophagy likely vary among different re-
ceptor tyrosine kinase subtypes.
Wei et al. (2013) identified three
conserved tyrosine residues in Beclin 1
that were phosphorylated by the EGFR
tyrosine kinase. The authors posited
that tyrosine phosphorylation at these
sites promotes Beclin 1 homodimeriza-
tion, dissociation of VPS34, and assem-
bly of the inactive Beclin 1-Rubicon-
Bcl-2 complex (Figure 1). Replacement
of the targeted tyrosines in Beclin 1
with phosphomimetic glutamic acid resi-dues generated a Beclin 1-EEE mutant
that acted as a dominant-negative-inhib-
itor of VPS34 activity and autophagy.
Importantly, Beclin 1-EEE-expressing
NSCLC cells failed to increase auto-
phagy during TKI exposure, which sup-
ports the hypothesis that this TKI
response hinges on the dephosphoryla-
tion of Beclin 1.
Tumor xenograft studies with NSCLC
cells engineered to express mutated
Beclin 1 proteins yielded striking results
(Wei et al., 2013). Beclin 1-EEE-express-
ing NSCLC cells formed faster-growing
tumors than those generated by wild-
type cells or cells bearing the corre-
sponding alanine substitution mutant of
Beclin 1 (Beclin 1-AAA), which cannot
be phosphorylated by the activated
EGFR. Interestingly, Beclin 1-EEE tumors
also exhibited higher levels of cell death
than wild-type or Beclin 1-AAA tumors.
This finding is consistent with the well-
established role of autophagy in meta-
bolic stress resistance; however, the
proliferative advantage conferred by
autophagy suppression apparently moreCell 154, September 12,than compensates for the
increased rate of cell death
in these Beclin 1-EEE
tumors.
Histologic analyses of the
Beclin 1-EEE tumors also
yielded some unanticipated
findings. Wei et al. (2013)
observed that, whereas the
wild-type and Beclin-AAA-ex-
pressing tumor tissues dis-
played the expected glandular
architecture associated with
lung adenocarcinomas, the
Beclin 1-EEE xenografts ex-
hibited a less well-differenti-
ated phenotype that resem-
bled adenosquamous lung
carcinoma, a NSCLC subtype
that carries a particularly
poor prognosis (Filosso et al.,
2011). Established Beclin
1-EEE tumors also displayed
significant resistance to TKI
treatment, suggesting that
the impaired autophagic
response to EGFR inhibition
was causally related to drug
resistance in these tumors.
As Wei et al. (2013) acknowl-
edge, it cannot be ruled outthat Beclin 1-EEE interferes with other
functions of endogenous Beclin 1 that
contribute to tumor growth and TKI resis-
tance in these studies.
The report by Wei et al. (2013) under-
scores the precept that the impact of
autophagy on tumor growth and pro-
gression is highly context dependent
(White, 2012). Furthermore, the study of-
fers a cautionary note regarding the clin-
ical application of autophagy inhibitors in
patients receiving TKI therapy for
NSCLC and other EGFR-linked cancers.
A more complete delineation of the re-
ceptor tyrosine kinases that govern
autophagy through tyrosine phosphory-
lation of Beclin 1 is clearly needed, as
is an understanding of the parameters
that dictate whether autophagy supports
or limits the growth of different tumor
types. Finally, emerging evidence that
autophagy modulates tumor histology
(Guo et al., 2013; Wei et al., 2013)
adds yet another variable that demands
further research if autophagy modulators
are to be used safely and effectively in
cancer.2013 ª2013 Elsevier Inc. 1185
REFERENCES
Choi, A.M., Ryter, S.W., and Levine, B. (2013).
N. Engl. J. Med. 368, 1845–1846.
Filosso, P.L., Ruffini, E., Asioli, S., Giobbe, R., Ma-
cri, L., Bruna, M.C., Sandri, A., and Oliaro, A.
(2011). Lung Cancer 74, 25–29.
Fung, C., Chen, X., Grandis, J.R., and Duvvuri, U.
(2012). Cancer Biol. Ther. 13, 1417–1424.
Guo, J.Y., Karsli-Uzunbas, G., Mathew, R., Aisner,
S.C., Kamphorst, J.J., Strohecker, A.M., Chen, G.,1186 Cell 154, September 12, 2013 ª2013 ElPrice, S., Lu, W., Teng, X., et al. (2013). Genes
Dev. 27, 1447–1461.
Han,W., Pan, H., Chen, Y., Sun, J., Wang, Y., Li, J.,
Ge, W., Feng, L., Lin, X., Wang, X., et al. (2011).
PLoS ONE 6, e18691.
Lorin, S., Hamai, A., Mehrpour, M., and Codogno,
P. (2013). Autophagy regulation and its role in can-
cer. Semin. Cancer Biol. Published online June 27,
2013. http://dx.doi.org/10.1016/j.semcancer.
2013.06.007.sevier Inc.Russell, R.C., Tian, Y., Yuan,H., Park,H.W.,Chang,
Y.Y., Kim, J., Kim, H., Neufeld, T.P., Dillin, A., and
Guan, K.L. (2013). Nat. Cell Biol. 15, 741–750.
Sithanandam, G., and Anderson, L.M. (2008). Can-
cer Gene Ther. 15, 413–448.
Wei, Y., Zongju, Z., Becker, N., Anderson, M.,
Sumpter, R., Xiao, G., Kinch, L., Koduru, P., Chris-
tudass, C.S., Veltri, R.W., et al. (2013). Cell 154, this
issue, 1269–1284.
White, E. (2012). Nat. Rev. Cancer 12, 401–410.Intrinsic Activity of Odorant
Receptors Guides Sensory Map Formation
John Ngai1,*
1Department of Molecular and Cell Biology, Helen Wills Neuroscience Institute and QB3 Functional Genomics Laboratory,
University of California, Berkeley, Berkeley, CA 94720, USA
*Correspondence: jngai@berkeley.edu
http://dx.doi.org/10.1016/j.cell.2013.08.037
Olfactory sensory neurons innervate the olfactory bulb in stereotyped patterns according to the
odorant receptors they express. A study by Nakashima et al. in this issue demonstrates that
the odorant receptor’s level of intrinsic activity—in the absence of activating odorant—influences
the guidance of olfactory axons to their targets.Olfactory sensory neurons (OSNs) typi-
cally express just one odorant receptor
(OR) from a repertoire of more than
1,000 OR genes (DeMaria and Ngai,
2010). OSNs expressing the same OR
are distributed across large areas of the
sensory epithelium and project their
axons to common and spatially invariant
sites—called glomeruli—in the olfactory
bulb. Individual glomeruli receive innerva-
tion only from OSNs expressing the same
OR; the spatial representation of ORs in
the bulb forms the anatomical basis of
the olfactory sensory map and reflects a
remarkable feat of pattern formation dur-
ing development. Targeting of olfactory
axons along the olfactory bulb’s dorsal-
ventral and medial-lateral axes occurs
through OR-independent mechanisms
(DeMaria and Ngai, 2010). In contrast,
‘‘receptor swaps’’ in which the coding
region of one OR gene is replaced with
the coding region of another OR cause
shifts in glomerular position along theanterior-posterior (AP) axis of the bulb
(Wang et al., 1998). A tantalizing hypothe-
sis emerging from these receptor swap
experiments posits that the OR not only
receives sensory information from small
volatile molecules in the environment but
also from axon guidance cues that deter-
mine where in the bulb the OSN’s axon
projects. This model, as appealing as it
may seem, has yet to receive compelling
experimental support.
If the OR does not function as an axon
guidance receptor per se, perhaps it
sets the responsiveness or ‘‘gain’’ of the
OSN to classical axon guidance cues
through its level of activity. But how?
ORs are unlikely to encounter their
cognate odorants in utero. Like other
G-protein-coupled receptors, in the
absence of ligand, ORs are intrinsically
active, existing in equilibrium between
an active and inactive state (Rosenbaum
et al., 2009). Given the sequence diversity
of ORs, it is not hard to imagine a similardiversity in the level of OR intrinsic activity
based on each receptor’s unique physical
properties. Initial support for this model
came froma demonstration that perturba-
tions in cyclic AMP (cAMP) signaling—the
second messenger pathway employed in
olfactory sensory transduction—altered
the projection of OSN axons along the
AP axis of the olfactory bulb (Imai et al.,
2006); decreased cAMP signaling led to
aberrant projections toward the anterior
bulb, whereas increased cAMP signaling
led to projections posterior to the location
of the normal glomerulus. Imai et al. (2006)
further demonstrated that expression of
Neuropilin1, a receptor for the repulsive
axon guidance cue Semaphorin 3A, is
regulated by cAMP (via protein kinase A)
in developing OSNs, neatly tying together
the OR and axon guidance. Direct evi-
dence that activity of unliganded receptor
influences OSN axon guidance—and
does so in an OR-specific way—was
nonetheless lacking.
